Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26965
Abstract: Cold agglutinin disease (CAD) is a rare, autoimmune, classical complement pathway (CP)-mediated hemolytic anemia. Sutimlimab selectively inhibits C1s of the C1 complex, preventing CP activation while leaving the alternative and lectin pathways intact. In Part… read more here.
Keywords: complement; agglutinin disease; sutimlimab; treatment ... See more keywords
Complement-directed therapy for cold agglutinin disease: sutimlimab.
Sign Up to like & getrecommendations! Published in 2023 at "Expert review of hematology"
DOI: 10.1080/17474086.2023.2218611
Abstract: INTRODUCTION Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defined as a distinct, low-grade lymphoproliferative disorder and characterized by the presence of immunoglobulin M (IgM) antibodies that recognize the "I" antigen… read more here.
Keywords: cad; agglutinin disease; complement; sutimlimab ... See more keywords
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014955
Abstract: Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did not receive a transfusion within… read more here.
Keywords: patients cold; agglutinin disease; sutimlimab; trial ... See more keywords